novo nordisk glp-1 medications Hims Inc Novo Nordisk launches its Wegovy

Learn more: #Pharma #ValueChains To view or add a comment, sign in Balancing GLP-1 Quality With Demand: A Live Discussion on the Future of Manufacturing and Scale The GLP-1 market is projected to nearly triple by 2030, reaching $156.7 billion globally, a growth trajectory that brings both opportunity and risk

Stock your kitchen with easy-to-digest foods before you start treatment

Without food to slow absorption, you may experience dizziness, nausea, or hypoglycemia more intensely

Almost all patients lose between 10% and 20% of their body weight

Indeed, CAPTURE, a multinational, crosssectional study [83] including 9823 adults with T2DM, found that less than 25% of T2DM patients are prescribed a glucose-lowering agent with proven cardiovascular benefit [83]

TRIUMPH-1 enrolled approximately 2,300 patients and is expected to complete around mid-year